Nasus Pharma (NSRX) Debt Ratio (2024)

Nasus Pharma (NSRX) posted Debt Ratio of 2.51 for Q4 2024.

Nasus Pharma (NSRX) Debt Ratio (2024) Analysis & Trends

Nasus Pharma (NSRX) has reported Debt Ratio for 1 consecutive years, with 2.51 the latest figure, recorded in Q4 2024.

Debt Ratio for Q4 2024 came in at 2.51, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was 2.51 (changed N/A YoY), and the FY2024 annual result was 2.51, changed N/A from the prior year.
Debt Ratio was 2.51 for Q4 2024 at Nasus Pharma.
Over five years, Debt Ratio peaked at 2.51 in Q4 2024 and troughed at 2.51 in Q4 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn	0.37
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn	0.27
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn	0.47
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn	-0.21
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn	0.38
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn	0.62
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn	0.39
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn	0.31
9	Novartis Ag	113.45 Bn	113.67 Bn	-	-
10	Nasus Pharma	28.20 Mn	23.91 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2024	2.51